Salvage Cryoablation for Recurrent Prostate Cancer Following Primary External Beam Radiotherapy or Primary Cryotherapy: a Propensity Score Matched Analysis of Mid-term Oncologic and Functional Outcomes
Scott P. Campbell,Sriram Deivasigamani,Rohith Arcot,Eric S Adams,Hazem Orabi,Ahmed Elshafei,Wei Phin Tan,Leah Davis,Yuan Wu,Andrew Chang,J Stephen Jones,Thomas J. Polascik
DOI: https://doi.org/10.1016/j.clgc.2023.06.015
IF: 3.121
2023-06-29
Clinical Genitourinary Cancer
Abstract:Introduction Local prostate cancer recurrence following radiotherapy (XRT) or cryoablation (CRYO) may be addressed with salvage cryotherapy (SCT), although little is known about how the main treatment modality affects SCT results. Oncologic and functional outcomes of patients who underwent SCT after primary XRT (XRT-SCT) or cryoablation (CRYO-SCT) were studied. Methods Data was collected using the Duke Prostate Cancer database and the Cryo On-Line Data (COLD) registry. The primary outcome is biochemical progression-free survival (BPFS). Urinary incontinence, rectourethral fistula, and erectile dysfunction were all secondary outcomes. To compare BPFS rates and identify impacting factors, the Kaplan-Meier log-rank test and univariable/multivariable Cox proportional hazards (CPH) models were utilized to identify factors that predict biochemical progression. On the multivariable CPH analysis, variables included in the model were age, PSA, PSAD, gleason score, D'Amico risk category, clinical stage, neoadjuvant treatment and treatment group (XRT-SCT vs. CRYO-SCT). Results 419 XRT-SCT and 63 CRYO-SCT patients met inclusion criteria, that was reduced to 63 patients in each cohort after propensity matching. There was no difference in BPFS at 2 and 5 years both before (p = 0.5 and p = 0.7) and after matching (p = 0.6 and p = 0.3). On multivariable CPH, BPFS was comparable between treatment groups (HR for CRYO-SCT 1.1 [0.2-2.2]). On the same analysis, BPFS was higher in D'Amico high-risk (HR 3.2, p < 0.01) and intermediate-risk (HR 1.95, p < 0.05)categories compared to low-risk. There was no significant difference in functional outcomes between cohorts. Conclusion Following primary cryotherapy, salvage cryoablation provides comparable intermediate oncological outcomes and functional outcomes compared to primary radiotherapy. The D'Amico risk group predicts oncologic outcomes, underlining significance of close monitoring after initial therapy in individuals with high or intermediate-risk PCa to detect recurrence in a timely manner Micro A retrospective study compared the oncologic and functional outcomes of salvage cryotherapy (SCT) after primary radiotherapy (XRT-SCT) and cryotherapy (CRYO-SCT). Survival analysis showed no difference in biochemical progression-free survival between cohorts at 2 and 5 years, and comparable functional outcomes, supporting that SCT may be used to treat local prostate cancer recurrence after XRT or Cryotherapy.
oncology,urology & nephrology